{
  "id": "61f5fb64882a024a1000001a",
  "type": "factoid",
  "question": "Which disease is treated with Tebentafusp?",
  "ideal_answer": "Tebentafusp is used for treatment of Metastatic Uveal Melanoma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32725406",
    "http://www.ncbi.nlm.nih.gov/pubmed/34551229",
    "http://www.ncbi.nlm.nih.gov/pubmed/34885078",
    "http://www.ncbi.nlm.nih.gov/pubmed/33839690",
    "http://www.ncbi.nlm.nih.gov/pubmed/32273508",
    "http://www.ncbi.nlm.nih.gov/pubmed/32816891"
  ],
  "snippets": [
    {
      "text": "Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34551229",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34551229",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "If approved, tebentafusp could become the standard of care for metastatic uveal melanoma-but only for those patients with a particular HLA allele.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33839690",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, a randomized phase III trial reported an overall survival benefit for tebentafusp in patients with untreated metastatic uveal melanoma. The aim of this comprehensive review is to summarize evidence of Gp-100 as a therapeutic target in melanoma, and the preclinical and clinical development of tebentafusp as a novel therapeutic strategy for patients with uveal melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34885078",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although UM metastases are less responsive than cutaneous melanoma to chemotherapy or immune checkpoint inhibitors, encouraging results have been reported with partial hepatectomy for solitary metastases, with percutaneous hepatic perfusion with melphalan or with tebentafusp.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32273508",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several alternative systemic therapeutic approaches have been or are currently being investigated, including two agents that have been taken into registration-intent clinical trials: tebentafusp, a T cell redirecting agent, and IDE196, an oral protein kinase C inhibitor. Treatment of advanced uveal melanoma remains challenging, however, encouraging results from novel agents offer hope for improvement in the near future.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32725406",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "melanoma received tebentafusp. Treatment efficacy, treatment-related adverse events, and biomarker assessments were performed for blood-derived and tumor biopsy samples obtained at baseline and on-treatment.RESULTS: Tebentafusp was generally well-tolerated and active in both patients with metastatic uveal melanoma and pati",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32816891",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Metastatic Uveal Melanoma"
}